State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market.

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

New rules require drugmakers to be clearer about explaining the risks and side effects of prescription drugs. The new ...

Weight loss injections are prescription drugs administered through the skin with ... Most insurance companies don’t currently ...

port director for Customs and Border Protection at New York's JFK Airport. CBP agents are on the front lines, intercepting counterfeit prescription drugs, which pour into the country. These include ...

While plenty of people rave about the weight loss results you can get from drugs like Ozempic, there’s also been a ton of ...

Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine Wegovy this Wednesday ... Distributors were still working through new ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...